IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.061
EU - Europa 7.617
AS - Asia 4.605
SA - Sud America 1.115
AF - Africa 290
Continente sconosciuto - Info sul continente non disponibili 166
OC - Oceania 12
Totale 28.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.874
GB - Regno Unito 1.711
CN - Cina 1.693
RU - Federazione Russa 1.291
SG - Singapore 1.231
IT - Italia 1.050
IE - Irlanda 1.008
BR - Brasile 881
UA - Ucraina 819
FR - Francia 521
SE - Svezia 446
HK - Hong Kong 443
VN - Vietnam 431
DE - Germania 349
KR - Corea 268
FI - Finlandia 220
ZA - Sudafrica 186
BD - Bangladesh 137
IN - India 85
CA - Canada 83
AR - Argentina 62
EC - Ecuador 50
MX - Messico 45
TR - Turchia 42
IQ - Iraq 39
ID - Indonesia 35
VE - Venezuela 34
CO - Colombia 31
NL - Olanda 31
PK - Pakistan 30
NG - Nigeria 28
AT - Austria 23
PL - Polonia 23
ES - Italia 21
JP - Giappone 21
UZ - Uzbekistan 21
SA - Arabia Saudita 18
PY - Paraguay 17
MA - Marocco 16
CL - Cile 15
BE - Belgio 14
AU - Australia 12
KE - Kenya 12
IL - Israele 11
JM - Giamaica 11
MY - Malesia 11
PH - Filippine 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
CZ - Repubblica Ceca 10
EU - Europa 10
LT - Lituania 10
EG - Egitto 9
HR - Croazia 9
JO - Giordania 9
TN - Tunisia 9
TT - Trinidad e Tobago 9
UY - Uruguay 9
GR - Grecia 8
PE - Perù 8
AZ - Azerbaigian 7
DZ - Algeria 7
NP - Nepal 7
AL - Albania 6
BO - Bolivia 6
TH - Thailandia 6
CI - Costa d'Avorio 5
ET - Etiopia 5
GT - Guatemala 5
HN - Honduras 5
OM - Oman 5
PT - Portogallo 5
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
EE - Estonia 4
IR - Iran 4
KG - Kirghizistan 4
LU - Lussemburgo 4
MD - Moldavia 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
SN - Senegal 4
BG - Bulgaria 3
KZ - Kazakistan 3
LV - Lettonia 3
NI - Nicaragua 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BH - Bahrain 2
DK - Danimarca 2
GE - Georgia 2
GY - Guiana 2
KH - Cambogia 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
Totale 28.683
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.468
Ashburn 1.349
Dallas 1.133
Woodbridge 1.013
Dublin 1.004
Seattle 903
Houston 785
Wilmington 763
Cambridge 732
Jacksonville 665
Singapore 665
Santa Clara 585
Chandler 555
Hong Kong 436
Moscow 406
Ann Arbor 366
Milan 363
San Jose 363
Beijing 361
Hefei 293
Council Bluffs 276
Seoul 265
Princeton 223
Nanjing 214
Siena 202
The Dalles 179
Johannesburg 167
Ho Chi Minh City 146
Los Angeles 133
Lauterbourg 123
Rome 111
Hanoi 95
San Diego 88
Columbus 80
Nanchang 80
Boardman 79
New York 78
São Paulo 75
Buffalo 74
Helsinki 73
Shenyang 61
London 47
Redondo Beach 45
Chicago 44
San Mateo 40
Figino 39
Hebei 39
Rio de Janeiro 38
Changsha 35
Shanghai 35
Jiaxing 31
San Francisco 31
Norwalk 30
Orem 30
Dong Ket 29
Frankfurt am Main 29
Brasília 28
Da Nang 28
Tianjin 28
Toronto 28
Abuja 27
Kunming 27
Turin 27
Flanders 25
Falls Church 24
Bengaluru 23
Menlo Park 23
Düsseldorf 22
Ningbo 22
Belo Horizonte 21
Guayaquil 21
Zhengzhou 21
Nuremberg 20
Philadelphia 20
Tashkent 20
Brooklyn 19
Jinan 18
Naples 18
Curitiba 17
Hangzhou 17
Tokyo 17
Guangzhou 16
Haiphong 16
Munich 16
Phoenix 16
Warsaw 16
Washington 16
Florence 15
Mexico City 15
Montreal 15
Quito 15
Baghdad 13
Boston 13
Dhaka 13
Brussels 12
Cape Town 12
Caracas 12
Goiânia 12
Newark 12
Totale 20.600
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 337
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 325
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 299
BRAF mutations in hairy-cell leukemia 288
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 282
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 275
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 269
Alternative methods of cladribine administration 263
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 259
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 256
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 254
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 251
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 248
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia 248
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 246
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells 245
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 244
Emerging drugs in chronic myelogenous leukaemia 241
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 239
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 237
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 237
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation 235
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 234
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 234
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 233
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma 232
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 231
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 229
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 228
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 227
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 227
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 227
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 227
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 225
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 224
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 224
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 223
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 223
Towards the pharmacotherapy of hairy cell leukaemia 222
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL 222
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 221
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 221
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 218
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia 218
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 218
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 216
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array 215
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 214
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 214
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia 214
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 213
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 213
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis 212
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 212
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 211
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 210
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 210
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 209
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 206
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 206
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 205
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 205
Predicting the clinical course of Hodgkin lymphoma 205
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 204
Bcr-abl peptides for chronic myeloid leukemia. 202
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 201
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study 201
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 198
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 198
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 197
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 195
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 195
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 194
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 193
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 192
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 192
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 191
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 186
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 186
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 185
IL-4 enhances expression and function of surface IgM in CLL cells 184
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 184
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 183
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 183
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 182
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights 182
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 181
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 181
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 179
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 178
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 178
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. 177
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 177
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 177
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 176
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 176
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas 176
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 176
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: Proliferation or anergy 174
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 173
Totale 21.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.673
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.673
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.145 0 0 0 96 71 54 86 49 87 194 165 343
2022/20232.071 156 118 308 288 217 441 33 154 241 24 57 34
2023/20241.289 67 32 66 121 30 374 448 6 7 16 9 113
2024/20253.341 89 173 218 156 455 203 73 208 274 149 313 1.030
2025/20267.480 629 1.267 876 823 1.030 301 650 324 260 330 265 725
2026/20271.505 403 260 801 41 0 0 0 0 0 0 0 0
Totale 28.866